NEW YORK (GenomeWeb) – The University of Michigan and Tempus have announced a collaboration on pancreatic cancer.

Under the terms of the deal, Chicago-based Tempus will provide genomic and gene expression sequencing and analysis to identify treatment opportunities for pancreatic cancer patients at Michigan's comprehensive cancer center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Sep
21
Sponsored by
Roche

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Oct
12
Sponsored by
PierianDx

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers. 

Oct
17
Sponsored by
Cofactor Genomics

This webinar will discuss the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.